Alphamab Oncology (stock name: ALPHAMAB-B) filed its Monthly Return for Equity Issuer for the period ended 31 May 2026. Key developments are as follows:

• Share Capital Structure – Authorised share capital remained unchanged at 25.10 billion ordinary shares with a par value of USD 0.000002, equivalent to authorised capital of USD 50,200.

• Issued and Treasury Shares – Issued shares (excluding treasury) increased by 88,000 to 968.66 million. – Treasury shares were unchanged at 5.72 million, keeping total issued shares at 974.38 million.

• Source of New Shares – All new shares arose from option exercises under the Post-IPO Share Option Plan; 88,000 options were exercised and 48,000 options lapsed during the month. – Option exercises generated HKD 0.42 million in cash proceeds.

• Outstanding Share Options – Pre-IPO Share Option Plan I: 9.21 million options outstanding. – Pre-IPO Share Option Plan II: 4.84 million options outstanding. – Post-IPO Share Option Plan: 0.98 million options outstanding after the month-end movements.

• Public Float Status – The company confirmed compliance with the Main Board’s 25% minimum public-float requirement as of 31 May 2026.

No movements were recorded in warrants, convertibles, or share award schemes during the month, and there were no changes to authorised capital. All share issues were duly authorised and complied with Hong Kong listing regulations.